Table 1. Summary of participant characteristics and pre-vaccination Treg values.
| Parameter | Influenza vaccine | Hepatitis B vaccine | Yellow fever vaccine |
|---|---|---|---|
| N participants | |||
| Placebo | 3 | 4 | 8 |
| Vaccine | 12 (Agrippal®) | 20 | 19 |
| Vaccine | 8 (Fluad®) | ||
| Age a | |||
| Placebo | 33 ± 2.65 | 30 ± 3.63 | 29 ± 2.00 |
| Vaccine | 27 ± 2.06 (Agrippal®) | 32 ± 1.47 | 30 ± 1.73 |
| Vaccine | 28 ± 2.05 (Fluad®) | ||
| Sex (M/F) a | |||
| Placebo | 1/2 | 2/2 | 5/3 |
| Vaccine | 3/9 (Agrippal®) | 17/3 | 12/7 |
| Vaccine | 4/4 (Fluad®) | ||
| Baseline frequency (%) a, b | |||
| CD4+CD45RA+FoxP3+ (rTreg) | 1.02 ± 0.09 | 4.04 ± 0.41 | 3.01 ± 0.21 |
| CD4+CD45RA-FoxP3++ (aTreg) | 0.99 ± 0.10 | 2.32 ± 0.21 | 2.44 ± 0.18 |
| Baseline frequency (%) within rTreg a, b | |||
| CD25 | 17.4 ± 1.1 | 13.5 ± 2.2 | 7.0 ± 0.9 |
| CD39 | 23.0 ± 2.7 | 25.2 ± 2.0 | 16.1 ± 0.9 |
| CD31 | n.d. | 85.8 ± 1.6 | 82.8 ± 1.3 |
| HLA-DR | n.d. | 52.5 ± 3.9 | 53.6 ± 1.5 |
| CCR4 | n.d. | 51.8 ± 4.0 | 50.9 ± 1.9 |
| CCR7 | 72.3 ± 3.5 | 63.5 ± 4.5 | 59.4 ± 2.1 |
| Baseline frequency (%) within aTreg a, b | |||
| CD25 | 58.0 ± 1.5 | 49.9 ± 2.7 | 51.5 ± 1.7 |
| CD39 | 67.1 ± 5.5 | 61.3 ± 5.6 | 66.3 ± 5.2 |
| CD31 | n.d. | 17.8 ± 3.7 | 15.3 ± 1.4 |
| HLA-DR | n.d. | 47.5 ± 3.5 | 43.5 ± 2.2 |
| CCR4 | n.d. | 76.7 ± 2.5 | 87.7 ± 1.1 |
| CCR7 | 41.2 ± 2.5 | 23.3 ± 3.2 | 19.3 ± 1.6 |
a mean ± SEM
b for influenza and yellow fever vaccines baseline is day 0, for hepatitis B vaccine baseline is day 168
n.d. = not determined